Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 201

1.

Tolerance induction in HLA disparate living donor kidney transplantation by facilitating cell-enriched donor stem cell Infusion: The importance of durable chimerism.

Leventhal JR, Ildstad ST.

Hum Immunol. 2018 May;79(5):272-276. doi: 10.1016/j.humimm.2018.01.007. Epub 2018 Mar 2. Review.

PMID:
29409743
2.

Intragraft Molecular Pathways Associated with Tolerance Induction in Renal Transplantation.

Gallon L, Mathew JM, Bontha SV, Dumur CI, Dalal P, Nadimpalli L, Maluf DG, Shetty AA, Ildstad ST, Leventhal JR, Mas VR.

J Am Soc Nephrol. 2018 Feb;29(2):423-433. doi: 10.1681/ASN.2017030348. Epub 2017 Nov 30.

PMID:
29191961
3.

Leukocyte iNOS is required for inflammation and pathological remodeling in ischemic heart failure.

Kingery JR, Hamid T, Lewis RK, Ismahil MA, Bansal SS, Rokosh G, Townes TM, Ildstad ST, Jones SP, Prabhu SD.

Basic Res Cardiol. 2017 Mar;112(2):19. doi: 10.1007/s00395-017-0609-2. Epub 2017 Feb 25.

4.

Delayed Donor Bone Marrow Infusion Induces Liver Transplant Tolerance.

Xie Y, Wu Y, Xin K, Wang JJ, Xu H, Ildstad ST, Leventhal J, Yang GY, Zhang Z, Levitsky J.

Transplantation. 2017 May;101(5):1056-1066. doi: 10.1097/TP.0000000000001684.

PMID:
28187014
5.

A Critical Role for TGF-β/Fc and Nonlytic IL-2/Fc Fusion Proteins in Promoting Chimerism and Donor-Specific Tolerance.

Xu H, Zheng XX, Zhang W, Huang Y, Ildstad ST.

Transplantation. 2017 Feb;101(2):294-301. doi: 10.1097/TP.0000000000001283.

PMID:
27306533
6.

Facilitating cells: Translation of hematopoietic chimerism to achieve clinical tolerance.

Ildstad ST, Leventhal J, Wen Y, Yolcu E.

Chimerism. 2015 Apr 3;6(1-2):33-9. doi: 10.1080/19381956.2015.1130780. Epub 2016 Jan 8.

7.

Characterization of Human CD8(+)TCR(-) Facilitating Cells In Vitro and In Vivo in a NOD/SCID/IL2rγ(null) Mouse Model.

Huang Y, Elliott MJ, Yolcu ES, Miller TO, Ratajczak J, Bozulic LD, Wen Y, Xu H, Ratajczak MZ, Ildstad ST.

Am J Transplant. 2016 Feb;16(2):440-53. doi: 10.1111/ajt.13511. Epub 2015 Nov 9.

8.

Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants.

Leventhal JR, Elliott MJ, Yolcu ES, Bozulic LD, Tollerud DJ, Mathew JM, Konieczna I, Ison MG, Galvin J, Mehta J, Badder MD, Abecassis MM, Miller J, Gallon L, Ildstad ST.

Transplantation. 2015 Feb;99(2):288-98. doi: 10.1097/TP.0000000000000605.

PMID:
25594553
9.

Facilitating cells in tolerance induction for kidney transplantation.

Yolcu ES, Leventhal JR, Ildstad ST.

Curr Opin Organ Transplant. 2015 Feb;20(1):57-63. doi: 10.1097/MOT.0000000000000156. Review.

PMID:
25522139
10.

DOCK2 is critical for CD8(+) TCR(-) graft facilitating cells to enhance engraftment of hematopoietic stem and progenitor cells.

Wen Y, Elliott MJ, Huang Y, Miller TO, Corbin DR, Hussain LR, Ratajczak MZ, Fukui Y, Ildstad ST.

Stem Cells. 2014 Oct;32(10):2732-43. doi: 10.1002/stem.1780.

11.

Regulatory B cells: the new "it" cell.

Goode I, Xu H, Ildstad ST.

Transplant Proc. 2014 Jan-Feb;46(1):3-8. doi: 10.1016/j.transproceed.2013.08.075. Epub 2013 Nov 8. Review.

PMID:
24216174
12.

The need for inducing tolerance in vascularized composite allotransplantation.

Ravindra KV, Xu H, Bozulic LD, Song DD, Ildstad ST.

Clin Dev Immunol. 2012;2012:438078. doi: 10.1155/2012/438078. Epub 2012 Oct 31. Review.

13.

Simultaneous bone marrow and composite tissue transplantation in rats treated with nonmyeloablative conditioning promotes tolerance.

Xu H, Ramsey DM, Wu S, Bozulic LD, Ildstad ST.

Transplantation. 2013 Jan 27;95(2):301-8. doi: 10.1097/TP.0b013e31827899fc.

14.

Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome.

Leventhal J, Abecassis M, Miller J, Gallon L, Tollerud D, Elliott MJ, Bozulic LD, Houston C, Sustento-Reodica N, Ildstad ST.

Transplantation. 2013 Jan 15;95(1):169-76. doi: 10.1097/TP.0b013e3182782fc1.

15.

Evolving approaches of hematopoietic stem cell-based therapies to induce tolerance to organ transplants: the long road to tolerance.

Leventhal J, Miller J, Abecassis M, Tollerud DJ, Ildstad ST.

Clin Pharmacol Ther. 2013 Jan;93(1):36-45. doi: 10.1038/clpt.2012.201. Epub 2012 Oct 10. Review.

16.

A critical role for the TLR4/TRIF pathway in allogeneic hematopoietic cell rejection by innate immune cells.

Xu H, Yan J, Zhu Z, Hussain LR, Huang Y, Ding C, Bozulic LD, Wen Y, Ildstad ST.

Cell Transplant. 2013;22(12):2367-80. doi: 10.3727/096368912X658881. Epub 2012 Nov 8.

17.

A clinically feasible approach to induce delayed tolerance in recipients of prior kidney or vascularized composite allotransplants.

Chen B, Xu H, Corbin DR, Ildstad ST.

Transplantation. 2012 Oct 15;94(7):671-8. doi: 10.1097/TP.0b013e318264fbc1.

PMID:
22948444
18.

Transplantation: is donor T-cell engraftment a biomarker for tolerance?

Xu H, Ildstad ST.

Nat Rev Nephrol. 2012 Oct;8(10):560-1. doi: 10.1038/nrneph.2012.187. Epub 2012 Aug 7. No abstract available.

PMID:
22868709
19.

Novel regulatory therapies for prevention of Graft-versus-host disease.

Leventhal J, Huang Y, Xu H, Goode I, Ildstad ST.

BMC Med. 2012 May 15;10:48. doi: 10.1186/1741-7015-10-48. Review.

20.

Immunology of vascularized composite allotransplantation: a primer for hand surgeons.

Ravindra K, Haeberle M, Levin LS, Ildstad ST.

J Hand Surg Am. 2012 Apr;37(4):842-50. doi: 10.1016/j.jhsa.2012.01.042.

PMID:
22464235
21.

Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation.

Leventhal J, Abecassis M, Miller J, Gallon L, Ravindra K, Tollerud DJ, King B, Elliott MJ, Herzig G, Herzig R, Ildstad ST.

Sci Transl Med. 2012 Mar 7;4(124):124ra28. doi: 10.1126/scitranslmed.3003509.

22.

Identification of inducible nitric oxide synthase in peripheral blood cells as a mediator of myocardial ischemia/reperfusion injury.

Guo Y, Sanganalmath SK, Wu W, Zhu X, Huang Y, Tan W, Ildstad ST, Li Q, Bolli R.

Basic Res Cardiol. 2012 Mar;107(2):253. doi: 10.1007/s00395-012-0253-9. Epub 2012 Feb 21.

23.

Innate and adaptive immune responses are tolerized in chimeras prepared with nonmyeloablative conditioning.

Xu H, Zhu Z, Huang Y, Bozulic LD, Hussain LR, Yan J, Ildstad ST.

Transplantation. 2012 Mar 15;93(5):469-76. doi: 10.1097/TP.0b013e318242bddf.

24.

Vascularized composite allotransplantation research: the emerging field.

Pomahac B, Becker YT, Cendales L, Ildstad ST, Li X, Schneeberger S, Siemionow M, Thomson AW, Zheng XX, Tullius SG.

Am J Transplant. 2012 Apr;12(4):1062-3. doi: 10.1111/j.1600-6143.2011.03900.x. Epub 2012 Jan 6. No abstract available.

25.

The role of pDC, recipient T(reg) and donor T(reg) in HSC engraftment: Mechanisms of facilitation.

Cardenas PA, Huang Y, Ildstad ST.

Chimerism. 2011 Jul;2(3):65-70. doi: 10.4161/chim.2.3.17588. Epub 2011 Jul 1.

26.

Vascularized composite allotransplantation at a crossroad.

Ravindra KV, Xu H, Ildstad ST.

Transplant Proc. 2011 Nov;43(9):3501-3. doi: 10.1016/j.transproceed.2011.10.011.

PMID:
22099829
27.

Immunosuppressive protocols and immunological challenges related to hand transplantation.

Ravindra KV, Ildstad ST.

Hand Clin. 2011 Nov;27(4):467-79, ix. doi: 10.1016/j.hcl.2011.07.001. Review.

PMID:
22051388
28.

Sensitized recipients exhibit accelerated but not hyperacute rejection of vascularized composite tissue allografts.

Wu S, Xu H, Chen B, Wen Y, Ikusika OM, Ocker A, Zhao H, Ildstad ST.

Transplantation. 2011 Sep 27;92(6):627-33. doi: 10.1097/TP.0b013e31822b9264.

29.

Differential outcomes in prediabetic vs. overtly diabetic NOD mice nonmyeloablatively conditioned with costimulatory blockade.

Bozulic LD, Huang Y, Xu H, Wen Y, Ildstad ST.

Exp Hematol. 2011 Oct;39(10):977-85. doi: 10.1016/j.exphem.2011.06.008. Epub 2011 Jul 1.

30.

Is durable macrochimerism key to achieving clinical transplantation tolerance?

Ildstad ST, Shirwan H, Leventhal J.

Curr Opin Organ Transplant. 2011 Aug;16(4):343-4. doi: 10.1097/MOT.0b013e328348e67a. No abstract available.

PMID:
21681096
31.

Evidence that FoxP3+ regulatory T cells may play a role in promoting long-term acceptance of composite tissue allotransplants.

Bozulic LD, Wen Y, Xu H, Ildstad ST.

Transplantation. 2011 Apr 27;91(8):908-15. doi: 10.1097/TP.0b013e31820fafb4.

32.

CD8α+ plasmacytoid precursor DCs induce antigen-specific regulatory T cells that enhance HSC engraftment in vivo.

Huang Y, Bozulic LD, Miller T, Xu H, Hussain LR, Ildstad ST.

Blood. 2011 Feb 24;117(8):2494-505. doi: 10.1182/blood-2010-06-291187. Epub 2010 Dec 29.

33.

Stem cell-based strategies for the treatment of type 1 diabetes mellitus.

Wen Y, Chen B, Ildstad ST.

Expert Opin Biol Ther. 2011 Jan;11(1):41-53. doi: 10.1517/14712598.2011.540235. Epub 2010 Nov 29. Review.

34.

Stem cell-based therapeutic applications in retinal degenerative diseases.

Huang Y, Enzmann V, Ildstad ST.

Stem Cell Rev. 2011 Jun;7(2):434-45. doi: 10.1007/s12015-010-9192-8. Review.

35.

A novel role of innate immune responses (toll-like receptor-4) in triggering graft-versus-host disease.

Huang Y, Ildstad ST.

Transplantation. 2010 Nov 27;90(10):1052-3. doi: 10.1097/TP.0b013e3181f86988. No abstract available.

PMID:
20844466
36.

Sensitization to minor antigens is a significant barrier in bone marrow transplantation and is prevented by CD154:CD40 blockade.

Xu H, Huang Y, Hussain LR, Zhu Z, Bozulic LD, Ding C, Yan J, Ildstad ST.

Am J Transplant. 2010 Jul;10(7):1569-79. doi: 10.1111/j.1600-6143.2010.03148.x.

37.

Bone marrow transplantation temporarily improves pancreatic function in streptozotocin-induced diabetes: potential involvement of very small embryonic-like cells.

Huang Y, Kucia M, Hussain LR, Wen Y, Xu H, Yan J, Ratajczak MZ, Ildstad ST.

Transplantation. 2010 Mar 27;89(6):677-85. doi: 10.1097/TP.0b013e3181c9dc7d.

38.

Dissociation between peripheral blood chimerism and tolerance to hindlimb composite tissue transplants: preferential localization of chimerism in donor bone.

Rahhal DN, Xu H, Huang WC, Wu S, Wen Y, Huang Y, Ildstad ST.

Transplantation. 2009 Sep 27;88(6):773-81. doi: 10.1097/TP.0b013e3181b47cfa.

39.

Composite tissue allotransplantation: current challenges.

Ravindra KV, Wu S, McKinney M, Xu H, Ildstad ST.

Transplant Proc. 2009 Nov;41(9):3519-28. doi: 10.1016/j.transproceed.2009.08.052. Review.

PMID:
19917338
40.

Plasmacytoid dendritic cells regulate autoreactive B cell activation via soluble factors and in a cell-to-cell contact manner.

Ding C, Cai Y, Marroquin J, Ildstad ST, Yan J.

J Immunol. 2009 Dec 1;183(11):7140-9. doi: 10.4049/jimmunol.0901175. Epub 2009 Nov 4.

41.

The beneficial effects of postinfarct cytokine combination therapy are sustained during long-term follow-up.

Sanganalmath SK, Stein AB, Guo Y, Tiwari S, Hunt G, Vincent RJ, Huang Y, Rezazadeh A, Ildstad ST, Dawn B, Bolli R.

J Mol Cell Cardiol. 2009 Oct;47(4):528-35. doi: 10.1016/j.yjmcc.2009.07.009. Epub 2009 Jul 16.

42.

Stem cells as tools in regenerative therapy for retinal degeneration.

Enzmann V, Yolcu E, Kaplan HJ, Ildstad ST.

Arch Ophthalmol. 2009 Apr;127(4):563-71. doi: 10.1001/archophthalmol.2009.65. Review.

43.

The history of human composite tissue allotransplantation.

Tobin GR, Breidenbach WC 3rd, Ildstad ST, Marvin MM, Buell JF, Ravindra KV.

Transplant Proc. 2009 Mar;41(2):466-71. doi: 10.1016/j.transproceed.2009.01.026. Review.

PMID:
19328905
44.

Composite tissue allotransplantation: past, present and future-the history and expanding applications of CTA as a new frontier in transplantation.

Wu S, Xu H, Ravindra K, Ildstad ST.

Transplant Proc. 2009 Mar;41(2):463-5. doi: 10.1016/j.transproceed.2009.01.027.

46.

Science of composite tissue allotransplantation.

Swearingen B, Ravindra K, Xu H, Wu S, Breidenbach WC, Ildstad ST.

Transplantation. 2008 Sep 15;86(5):627-35. doi: 10.1097/TP.0b013e318184ca6a. Review.

47.

Composite tissue transplantation: a rapidly advancing field.

Ravindra KV, Wu S, Bozulic L, Xu H, Breidenbach WC, Ildstad ST.

Transplant Proc. 2008 Jun;40(5):1237-48. doi: 10.1016/j.transproceed.2008.04.003. Review.

48.

Plasmacytoid precursor dendritic cells from NOD mice exhibit impaired function: are they a component of diabetes pathogenesis?

Huang Y, Fugier-Vivier IJ, Miller T, Elliott MJ, Xu H, Bozulic LD, Chilton PM, Ildstad ST.

Diabetes. 2008 Sep;57(9):2360-70. doi: 10.2337/db08-0356. Epub 2008 Jun 20.

49.

Fms-related tyrosine kinase 3 expression discriminates hematopoietic stem cells subpopulations with differing engraftment-potential: identifying the most potent combination.

Huang Y, Ratajczak MZ, Reca R, Xu H, Tanner M, Rezzoug F, Hussain LR, Fugier-Vivier I, Bolli R, Ildstad ST.

Transplantation. 2008 Apr 27;85(8):1175-84. doi: 10.1097/TP.0b013e31816a89cf.

PMID:
18431239
50.

TNF-alpha is critical to facilitate hemopoietic stem cell engraftment and function.

Rezzoug F, Huang Y, Tanner MK, Wysoczynski M, Schanie CL, Chilton PM, Ratajczak MZ, Fugier-Vivier IJ, Ildstad ST.

J Immunol. 2008 Jan 1;180(1):49-57.

Supplemental Content

Loading ...
Support Center